

WO 00/28072


WO 00/28072


1/17

PCT/US99/26133

09/831123

FIG. 1









Figure 4




FIG. 5A




FIG. 5B

09831123 084304




FIG. 6




FIG. 7A**FIG. 7B**

FIG. 8

- HOOH oxidized HSA containing 27.9 pmol cysteic acid/μg protein
▨ HOOH oxidized HSA containing 11.7 pmol cysteic acid/μg protein
■ HOOH oxidized HSA containing 4.0 pmol cysteic acid/μg protein
▢ Unoxidized HSA




FIG. 9A





FIG. 9B

Figure 10


Reactivity of mAb against PAoxBSA and unoxidized BSA




11/17

Figure 11
Plate A - 96-well template

	1	2	3	4	5	6	7	8	9	10	11	12
A	K2.F1.1	K2.F1.1	K2.F1.1	K2.F1.1	1 μ g K2.F1.3	PAox K2.F1.3	OVA + GSA K2.F1.3	K2.F1.6	K2.F1.6	K2.F1.6	K2.F1.6	
B	K2.F1.1	K2.F1.1	K2.F1.1	K2.F1.1	1 μ g K2.F1.3	PA K2.F1.3	ox OVA K2.F1.3	K2.F1.3	K2.F1.6	K2.F1.6	K2.F1.6	
C	K2.F1.1	K2.F1.1	K2.F1.1	K2.F1.1	1 μ g C K2.F1.3	M-OVA K2.F1.3	M.OVA K2.F1.3	K2.F1.3	K2.F1.6	K2.F1.6	K2.F1.6	
D	K2.F1.1	K2.F1.1	K2.F1.1	K2.F1.1	1 μ g OVA K2.F1.3	OVA K2.F1.3	OVA K2.F1.3	K2.F1.3	K2.F1.6	K2.F1.6	K2.F1.6	
E	K2.F1.1	K2.F1.1	K2.F1.1	K2.F1.1	1 μ g OVA K2.F1.3	-oxCAP K2.F1.3	37 noxCA K2.F1.3	K2.F1.3	K2.F1.6	K2.F1.6	K2.F1.6	
F	K2.F1.1	K2.F1.1	K2.F1.1	K2.F1.1	1 μ g OVA-u K2.F1.3	noxCA K2.F1.3	P 37 K2.F1.3	K2.F1.3	K2.F1.6	K2.F1.6	K2.F1.6	
G	K2.A12	1 μ g PA K2.A12	ox OV A K2.A12	K2.A12	1 μ g OVA- K2.A12	oxCAP K2.A12	37 K2.A12	K2.A12	K2.A12	K2.A12	K2.A12	
H	K2F1.1	K2.F1.1	K2.F1.1	K2.F1.1	1 μ g PAox K2.F1.3	PAox K2.F1.3	OVA + CA K2.F1.3	K2.F1.3	K2.F1.6	K2.F1.6	K2.F1.6	








FIG. 14





Figure 15 - Bailey Renal Patients Plasma 1:200




Figure 16A




Figure 16B